Strengths

Baxter’s diversified hospital and renal portfolio supports broad customer access versus narrower medtech peers, reducing dependence on any single procedure or therapy line.

Its essential-care product mix in IV solutions, infusion, and renal therapies creates recurring demand that is typically less cyclical than elective-device peers.

Global manufacturing and distribution scale help Baxter serve large health systems efficiently, giving it a reach advantage over smaller specialty competitors.

The company’s installed base and clinical integration in hospital workflows can support switching friction versus peers with less embedded product usage.

Weaknesses

Negative TTM ROIC indicates Baxter is destroying capital versus higher-return peers, signaling weaker structural profitability and capital allocation efficiency.

Net debt to EBITDA above 10x remains materially elevated versus most large-cap medtech peers, constraining financial flexibility and raising refinancing sensitivity.

A cash conversion cycle above 114 days implies working-capital intensity that is worse than leaner peers, limiting free-cash-flow conversion.

Current and quick ratios are adequate but not strong, leaving Baxter less resilient than peers with cleaner balance sheets and stronger liquidity buffers.

Opportunities

Operational simplification and supply-chain improvement could narrow Baxter’s working-capital gap versus peers, improving cash generation without requiring major demand growth.

Portfolio focus on higher-value hospital and renal franchises could lift mix and margin relative to peers with more commoditized product exposure.

If execution stabilizes, Baxter can leverage its installed base and global reach to recover share in core care settings where switching costs remain meaningful.

Debt reduction from improved cash flow would strengthen positioning versus leveraged peers by lowering interest burden and expanding strategic flexibility.

Threats

Highly leveraged peers may still outinvest Baxter in innovation and commercial execution, widening competitive gaps if its balance-sheet burden persists.

Persistent hospital pricing pressure can compress margins more severely for Baxter than for peers with stronger proprietary differentiation and pricing power.

Supply-chain disruptions or quality issues would be especially damaging because Baxter’s long cash cycle and leverage leave less operational cushion than peers.

If capital markets tighten, Baxter’s elevated debt load could become a relative disadvantage versus better-capitalized medtech competitors.

Overall Score

Baxter’s essential-care scale and embedded hospital presence provide some structural support, but leverage, weak returns, and poor cash conversion leave it below stronger peers overall.